Sofinnova Partners Secures €1.2 Billion to Drive Life Sciences Innovation

Sofinnova Partners, a prominent European venture capital firm specializing in life sciences, has raised €1.2 billion across its investment strategies over the past year, including over €1 billion secured in the last quarter alone. This significant fundraising effort brings the firm’s assets under management (AUM) to more than €4 billion, reinforcing its standing as a leading supporter of innovation in healthcare and sustainability. Details on specific funds will be disclosed upon their final closings.

The fresh capital will enable Sofinnova to support 50 to 60 new companies across its seven investment strategies, which range from incubation to later-stage growth. The firm’s investment focus spans biotech, medtech, industrial biotechnology, and digital medicine, positioning it to help address some of the world’s critical health and sustainability challenges.

The firm’s latest funds have garnered strong interest from institutional investors, sovereign wealth funds, corporates, and family offices. This level of commitment highlights the confidence the investment community places in Sofinnova’s approach to identifying and nurturing high-potential opportunities.

Sofinnova Partners has established itself as one of the most experienced and globally connected teams in life sciences investing. The firm has over 80 professionals, including 25 investment partners with deep sector expertise. With offices in Paris, London, and Milan, the team represents 24 nationalities and maintains a presence in key innovation hubs worldwide.

In addition to expanding its reach, Sofinnova Partners is integrating advanced technology into its investment process. The firm recently launched Sofinnova.ai, an AI-powered platform developed over the past five years to enhance how it sources, evaluates, invests in, and supports groundbreaking science and entrepreneurs. By leveraging advanced data analytics and machine learning, Sofinnova is strengthening its ability to identify disruptive innovations and accelerate the growth of pioneering life sciences companies.

About Sofinnova Partners

Founded in 1972, Sofinnova Partners is a leading venture capital firm in life sciences with a strong focus on healthcare and sustainability. The firm actively partners with entrepreneurs as a lead or cornerstone investor, supporting the development of transformative innovations that positively impact the global community. With 50 years of experience, Sofinnova Partners has backed over 500 companies and continues to build market leaders worldwide. The firm currently manages more than €4 billion in assets from its offices in Paris, London, and Milan.